iotrolan has been researched along with Hakim Syndrome in 1 studies
iotrolan: nonionic, isotonic contrast medium designed for intrathecal use; RN given refers to cpd without isomeric designation; DL-3-117 refers to stereoisomer; structure given in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kono, K | 1 |
| Sugita, Y | 1 |
| Funaki, C | 1 |
| Kuzuya, M | 1 |
| Hayashi, T | 1 |
| Yamada, K | 1 |
| Tajima, T | 1 |
| Suzuki, Y | 1 |
| Iguchi, A | 1 |
| Yamamoto, T | 1 |
1 other study available for iotrolan and Hakim Syndrome
| Article | Year |
|---|---|
[Occult CSF flow disturbance of patients with Alzheimer type dementia and vascular dementia--results from iotrolan CT-cisternography].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia, Vascular; Female; Humans; Hydrocephalus, Norma | 1994 |